Hemato Oncology Testing Market Trends Size, Growth, Report Study, Demand, Key Players | 2022–2027Posted by Priya on May 22nd, 2023 Growth in this market is driven by the rising global prevalence of hematologic cancer, growing awareness regarding personalized medicines, and increasing collaborations for developing new assays. On the other hand, Uncertain reimbursement scenario in different regions is expected to restrain the growth of this market during the forecast period. What the Hemato Oncology Testing Market Looks Like? The global Hemato Oncology Testing Market boasts a total value of .9 billion in 2022 and is projected to register a growth rate of 14.2% to reach a value of .6 billion by 2027 ![]() Based on product & services, the hemato oncology testing is segmented into services and assay kits. In 2018, the services segment accounted for the largest share of the hemato oncology testing. This is mainly due to the increasing prevalence & incidence of leukemia, non-Hodgkin lymphoma, and myeloma cancers. Apart from this, rising awareness regarding advanced treatment therapies such as personalized medicine is also driving the growth of this segment. Based on the technology, the market has been segmented further into five subsegments, viz., PCR, IHC, NGS, cytogenetics, and other technologies. Among these, the PCR segment is estimated to dominate the market in 2019, due to the extensive use of this technology owing to its ease of use and easy availability of assay kits. However, NGS is expected to grow at the highest growth rate in the coming years due to its advantages, such as more specificity and sensitivity. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877 What Drives the Hemato Oncology Testing Market? The growth of the global market for Hemato Oncology Testing Market is primarily influenced by the following factors:
Geographical growth scenario of Hemato Oncology Testing Market: North America accounted for the largest share of the Ambulatory surgical centers market, followed by Europe. The large share of this region can be attributed to the high adoption of Ambulatory surgical centers for reducing the soaring healthcare costs, increasing volume of surgical procedures performed, and the presence of significant market players, such as Epic Systems Corporation (US), Cerner Corporation (US), McKesson Corporation (US), Philips Healthcare (Netherlands), and Allscripts Healthcare Solutions, Inc. (US). Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877 Leading market players and strategies adopted Prominent players in the hemato oncology testing market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US). Like it? Share it!More by this author |